Jump to any asset
849 assets, updated daily
As of October 10, 2026, CRISPR Therapeutics AG (CRSP) trades at $53.39. CleaRank Financial AI rates it Hold with a fair value of $79.88, 49.6% above the current price. Wall Street's consensus target is $80.00 across 22 analysts. RSI at 38 is in neutral territory, and the price is below its 50-day average of $54.99.
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG NASDAQ
$53.39
2.950 (5.85%)
At close: Oct 9, 4:00 PM EDT
AI Analyst Consensus
59 / 100
CRISPR Therapeutics AG (CRSP) is currently trading at $53.39, below its 50-day moving average of $54.99 but above its 200-day moving average of $53.23. The stock exhibits bearish momentum, as indicated by an RSI of 37.72. Wall Street analysts maintain a 'Hold' consensus with a median price target of $80, suggesting a potential upside of 49.8% from current levels. The company has demonstrated exceptional revenue growth, with current year estimates at $40.8 million, a 1063.00% increase year-over-year, and projected to grow by 283.00% next year to $61.2 million. Insiders have shown conviction, with a "Moderate Buy Signal" indicated by net selling of $422.3M million against $19.2 million in sales. This insider activity, coupled with significant revenue growth projections, presents a potential upside. However, the current technical indicators suggest near-term weakness, and the company's negative EPS and profit margins warrant caution. The biotechnology sector, represented by the XLV ETF, shows a median P/E of -11.26 and revenue growth of 8.1%, against which CRSP's revenue growth is exceptional, but its valuation metrics like price-to-sales at 387.18 are significantly higher.
CRSP Price Analysis
Market Metrics
Open
$50.82
Day Range
$50.52 to $54.07
Prev Close
$50.44
Volume
1.47M
52-Week Range
$44.12 to $78.48
Market Cap
$5.16B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, CRSP trades at 387.18x, far above the sector average of 3.70x.
CRSP Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 3 quarters, CRSP beat estimates 1 times. The stock rose 1 times the next day. Price tends to react positively to beats.
CRSP Analysis
Company's Health
3/5
AI Technical Analysis
CRISPR Therapeutics AG (CRSP) is exhibiting bearish momentum with an RSI reading of 37.72, indicating a potential for further downside or a period of consolidation. The stock is trading below its 50-day SMA ($54.99) and 20-day EMA ($54.56), but remains above its 200-day SMA ($53.23), suggesting that the longer-term trend is still intact, albeit under pressure. Key support is found at the 200-day SMA, while resistance lies at the 50-day SMA. Volume on the latest trading day was 1,465,700, which is 11.3% below the average volume, indicating a lack of strong conviction from either buyers or sellers at current levels. The MACD at -0.52 also suggests a bearish trend. Investors should monitor the price action around the 200-day SMA for signs of a potential reversal or continuation of the current bearish trend.
ProTips
- Monitor CRISPR Therapeutics AG's upcoming earnings reports closely for signs of improving profitability and positive EPS surprises, which could validate the current 'Hold' rating and price targets.
- Given the bearish technical momentum (RSI 37.72, below 50-day SMA), consider waiting for a confirmed technical reversal or a break above key resistance levels before initiating new positions.
- The significant revenue growth projected for CRISPR Therapeutics AG is a key driver, but investors should remain aware of the company's negative EPS and high P/S ratio, emphasizing the speculative nature of this investment.
Key Catalysts
Bullish
Positive Insider Buying Activity
Insiders have demonstrated significant conviction with net purchases totaling $52.6 million against $19.2 million in sales, indicating a 'Moderate Buy Signal' and potentially signaling confidence in future growth.
Source: Insider Trading DataBullish
Strong Revenue Growth Projections
CRISPR Therapeutics AG is projected to achieve substantial revenue growth, with current year estimates at $40.8 million (+1063.00% YoY) and next year at $61.2 million (+283.00% YoY), which could drive future valuation.
Source: Wall Street EstimatesBearish
Negative Profitability and High Valuation
The company continues to report negative EPS (-4.74) and profit margins, while trading at a high price-to-sales ratio of 387.18, posing a risk if profitability does not materialize.
Source: Company FinancialsBearish
Bearish Technical Momentum
The stock's current technical indicators, including an RSI of 37.72 and trading below its 50-day SMA, suggest bearish momentum and potential for further price declines in the short term.
Source: Technical Analysis DataMarket Outlook
CRISPR Therapeutics AG (CRSP) is expected to see continued strong revenue growth over the next few years, with next year's revenue projected at $61.2 million, a 283.00% increase. The base case price projection for 2030 is $79.88, implying a significant upside from current levels. This outlook is supported by the company's innovative gene-editing technology and the positive insider sentiment, with net buyers accounting for a substantial portion of recent transactions. However, the path forward is not without challenges. The company must demonstrate a clear path to profitability to justify its high valuation, as current EPS and profit margins remain negative. A failure to translate revenue growth into net income could lead to a significant re-rating of the stock. Upside catalysts could include successful clinical trial results or strategic partnerships, while downside risks include regulatory hurdles, competitive pressures from other gene-editing companies like EDIT and NTLA, or a broader market downturn impacting speculative biotechnology stocks.
Key Statistics
| Market Cap | 5.16B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -4.74 |
| Dividend Yield | 0.00% |
| 52 Week High | 78.48 |
| 52 Week Low | 44.12 |
CRISPR Therapeutics AG (CRSP) presents a mixed fundamental picture, with exceptional revenue growth contrasting with negative profitability and a high valuation. The company's price-to-sales ratio stands at 387.18, significantly above the healthcare sector median of 3.7, indicating a substantial premium. While current year revenue is projected to grow by 1063.00% to $40.8 million, and next year by 283.00% to $61.2 million, the company reports a negative EPS of -4.74 and a negative profit margin of 0.00%. The return on equity is -26.10%, and the operating margin is a significantly negative -1,127.55%, highlighting significant operational inefficiencies or high research and development costs. The debt-to-equity ratio is 0.45, which is below the sector median of 0.45, suggesting a manageable debt load. Despite the strong revenue growth outlook, the current valuation appears stretched given the lack of profitability and negative earnings.
Earnings & Growth Analysis
CRISPR Therapeutics AG (CRSP) most recently reported earnings for the quarter ending June 2026, with an EPS of $0.89, beating the estimate of $0.87 by 2.3%. This positive surprise was accompanied by a 0.19% increase in stock price. Prior to this, the company missed estimates in the March 2026 quarter, reporting an EPS of -1.28 against an estimate of -1.23, a -4.07% surprise, which led to a 2.24% stock price decline. The company has shown inconsistency in earnings performance, with a notable beat in March 2026 (EPS $0.15 vs. estimate $0.06) followed by misses. The forward-looking EPS estimates remain negative for the current and next quarters, suggesting continued losses in the near term, though revenue growth projections are strong.
Key Risks
CRISPR Therapeutics AG (CRSP) faces significant risks including its high valuation, evidenced by a price-to-sales ratio of 387.18, far exceeding the sector median. The company's persistent negative earnings and profit margins, with an EPS of -4.74, present a considerable risk, especially if revenue growth projections do not materialize or if funding becomes constrained. Also, the current technical setup shows bearish momentum with the RSI at 37.72 and the stock trading below its 50-day moving average, indicating potential for further price declines.
Technical Indicators
| RSI (14) | 37.72 |
|---|---|
| MACD | -0.52 |
| SMA 50 | 54.99 |
| SMA 200 | 53.23 |
RSI
Bearish
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($54.99) above the 200-day SMA ($53.23), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.41
Moderate correlation
Nasdaq 100 (QQQ)
+0.40
Weak correlation
Bitcoin (BTC)
+0.15
Weak correlation
Gold (XAU)
+0.18
Weak correlation
Check Custom Correlation
How does any other asset move with CRSP? One year of daily closes, Pearson correlation.
Try
CRSP Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$52.86
Slight discount to current
Wait for small dip
Aggressive
$53.39
At current price
Enter now if confident
Risk Management
STOP LOSS
$47.29
MAX LOSS
-10.5%
Volatility-Adjusted Stop Loss
Calculated based on RSI (37.7) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$54.44
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$55.50
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$57.08
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
CRSP is classified as a high-volatility asset (Daily Vol: 3.17%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on October 10, 2026.Growth of $10,000
A $10,000 investment in CRSP in October 2016 would be worth about $37,892 today, compared with about $36,334 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CRSP today could grow to about $27,377 by 2036 in the base case, with a bull case near $207,701 and a bear case around $3,609. Projections are statistical simulations, not guarantees.
CRSP Stock Price Prediction: 2030
CleaRank's simulation projects a price near $79.88 for CRSP by 2030 in the base case, from $53.39 today (1.5x over 4 years). The downside path ends near $22.17. These are outcomes of a Monte Carlo simulation run on CRSP's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $31.11 | $59.05 | $112 |
| 2028 | $26.39 | $65.30 | $162 |
| 2029 | $23.80 | $72.22 | $219 |
| 2030 | $22.17 | $79.88 | $288 |
| 2031 | $21.08 | $88.34 | $370 |
| 2032 | $20.33 | $97.70 | $469 |
| 2033 | $19.83 | $108 | $589 |
| 2034 | $19.51 | $120 | $732 |
| 2035 | $19.33 | $132 | $904 |
| 2036 | $19.27 | $146 | $1,109 |
Method: 10,000 simulated price paths using CRSP's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. CRSP is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
CRSP Insider Trading Analysis
Bought
$52.6M
2 Transactions
Sold
$19.2M
23 Transactions
Insiders
8
Active Traders
Avg Transaction
$2.9M
Large trades
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 14, 2018 | EMSTER KURT VON
Director
|
Sell | 650.0K | $35.4M |
| Dec 7, 2020 | BOLZON BRADLEY J
Director
|
Sell | 171.0K | $26.4M |
| Feb 19, 2021 | BOLZON BRADLEY J
Director
|
Sell | 171.0K | $25.5M |
| Dec 4, 2017 | CELGENE CORP
Beneficial Owner of more than 10% of a Class of Security
|
Sell | 1.1M | $21.1M |
| Mar 23, 2021 | KLEIN LAWRENCE OTTO
Chairman of the Board
|
Sell | 100.0K | $12.8M |
| Nov 30, 2020 | NOVAK RODGER
President
|
Sell | 100.0K | $12.5M |
| Apr 27, 2018 | BOLZON BRADLEY J
Director
|
Sell | 222.3K | $11.1M |
| Apr 27, 2018 | WOIWODE THOMAS
Director
|
Sell | 222.3K | $11.1M |
| Jun 29, 2021 | BOLZON BRADLEY J
Director
|
Sell | 47.5K | $7.1M |
| May 8, 2018 | BOLZON BRADLEY J
Director
|
Sell | 129.0K | $6.5M |
Page 1 of 1
Frequently Asked Questions
What is CRISPR Therapeutics AG's stock price prediction for 2030?
Based on Monte Carlo simulations, CRISPR Therapeutics AG's stock price is projected to be $79.88 in 2030 under a base case scenario. The downside projection is $22.17, while the upside projection reaches $287.74. These figures represent statistical outcomes and are not guarantees.
Is CRISPR Therapeutics AG stock a buy right now?
CRISPR Therapeutics AG (CRSP) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $80 suggesting a 49.8% upside. While insiders are net sellers and revenue growth is exceptional, the stock exhibits bearish technical momentum and negative profitability, making it a speculative buy at best.
What are the key risks for CRISPR Therapeutics AG?
The primary risks for CRISPR Therapeutics AG include its extremely high valuation (P/S ratio of 387.18), persistent negative earnings and profit margins, and current bearish technical momentum. The company's ability to achieve its ambitious revenue growth targets is also a key factor.
How does CRISPR Therapeutics AG compare to its sector peers?
CRISPR Therapeutics AG operates in the Healthcare sector, with an ETF proxy of XLV. While its revenue growth is exceptionally high compared to the sector median of 8.1%, its valuation metrics like P/S (387.18) are significantly higher than the sector median of 3.7. The company also lags in profitability metrics like ROE (-26.10%) compared to the sector median of 6.9%.
What is the recent earnings performance of CRISPR Therapeutics AG?
CRISPR Therapeutics AG recently reported an EPS of $0.89 for the quarter ending June 2026, beating estimates by 2.3%. However, the company has a history of inconsistent earnings, including a miss in the March 2026 quarter, and forward EPS estimates remain negative.
What is the insider sentiment for CRISPR Therapeutics AG?
Insider sentiment for CRISPR Therapeutics AG is currently positive, with a 'Moderate Buy Signal' indicated by net selling of $422.3M million against $19.2 million in sales. This suggests a degree of confidence from company management in its future prospects.
What are the revenue growth prospects for CRISPR Therapeutics AG?
CRISPR Therapeutics AG has strong revenue growth prospects, with current year estimates at $40.8 million (+1063.00% YoY) and next year projected to reach $61.2 million (+283.00% YoY). This significant growth is a key factor supporting the company's valuation.